FATE on Nasdaq

Fate Therapeutics

A clinical-stage biopharmaceutical company in San Diego, United States.1

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Eloxx Pharmaceuticals, Inc., Evaxion A/S or DBV Technologies, or pick any stock.

  • TickerFATE on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersSan Diego, United States1
  • Websitefatetherapeutics.com
  • Legal formDelaware corporation1
  • Business address12278 Scripps Summit Drive, San Diego, Ca 921313
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Fate Therapeutics image from its website
Image: fatetherapeutics.com4

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-2222.4%Operating margin5
-2051.1%Net margin5
-51.2%Revenue growth, 20255
-65.8%Return on equity5
-$112.0MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$107.8M
  • Income tax0¢$2.0K

Out of $6.6M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$6.6M in 2025−38% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $10.7M$10.7M20192020: $31.4M$31.4M2020+194%2021: $55.8M$55.8M2021+78%2022: $96.3M$96.3M2022+72%2023: $63.5M$63.5M2023−34%2024: $13.6M$13.6M2024−79%2025: $6.6M$6.6M2025−51%
Operating income67895-$147.7M in 2025+47% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M02019: -$100.7M-$100.7M20192020: -$128.1M-$128.1M2020+27%2021: -$217.0M-$217.0M2021+69%2022: -$308.4M-$308.4M2022+42%2023: -$190.5M-$190.5M2023−38%2024: -$210.3M-$210.3M2024+10%2025: -$147.7M-$147.7M2025−30%
Net income67895-$136.3M in 2025+39% since 2019
-$300.0M-$200.0M-$100.0M02019: -$98.1M-$98.1M20192020: -$173.4M-$173.4M2020+77%2021: -$212.2M-$212.2M2021+22%2022: -$281.7M-$281.7M2022+33%2023: -$160.9M-$160.9M2023−43%2024: -$186.3M-$186.3M2024+16%2025: -$136.3M-$136.3M2025−27%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Collaboration revenue$6.6M$13.6M
Research and development$107.8M$135.0M
General and administrative$46.5M$74.2M
Impairment loss$0$14.7M
Total operating expenses$154.3M$223.9M
Loss from operations-$147.7M-$210.3M
Interest income$11.1M$17.3M
Change in fair value of stock price appreciation milestones$244.0K$819.0K
Other income$93.0K$5.9M
Total other income$11.4M$24.0M
Net loss-$136.3M-$186.3M
Unrealized gain (loss) on available-for-sale securities, net-$152.0K$253.0K
Comprehensive loss-$136.5M-$186.0M
Net loss per share, Basic-$1.15-$1.64
Net loss per share, Diluted-$1.15-$1.64
Weighted-average common shares used to compute basic net loss per share118.8M shares113.7M shares
Weighted-average common shares used to compute diluted net loss per share118.8M shares113.7M shares

Compare Fate Therapeutics with another company

Leadership

Who has led Fate Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. J. Scott Wolchko2016–2024
  2. Bahram Valamehr2025–now

President

  1. J. Scott Wolchko2016–2024
  2. Bahram Valamehr2025–now

Chief financial officer

  1. J. Scott Wolchko2015
  2. Edward J. Dulac Iii.2020–2024
  3. Kamal Adawi2025–now

Chief operating officer

  1. J. Scott Wolchko2015
201520202025
Board members and other officers (32)

Timeline

  1. Jan 13, 2025New chief executive Bahram Valamehr becomes CEO13
  2. Jan 14, 2016New chief executive J. Scott Wolchko becomes CEO14
  3. Apr 27, 2007Founded Fate Therapeutics is founded47

Filings

335 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 170 insider forms, 33 large holders, 64 other. The latest 20:

  1. Sep 28, 20268-K EDGAR
  2. Aug 13, 2026S-8 EDGAR
  3. Aug 13, 202610-Q EDGAR
  4. Aug 13, 20268-K EDGAR
  5. Aug 5, 20264 EDGAR
  6. Aug 5, 20264 EDGAR
  7. Aug 4, 2026144 EDGAR
  8. Aug 4, 2026144 EDGAR
  9. Jul 8, 2026SCHEDULE 13G/A EDGAR
  10. Jun 15, 20264 EDGAR
  11. Jun 15, 20264 EDGAR
  12. Jun 15, 20264 EDGAR
  13. Jun 15, 20264 EDGAR
  14. Jun 15, 20264 EDGAR
  15. Jun 15, 20264 EDGAR
  16. Jun 15, 20264 EDGAR
  17. Jun 15, 20263 EDGAR
  18. Jun 15, 20268-K EDGAR
  19. Jun 15, 20264 OWNERSHIP DOCUMENT EDGAR
  20. Jun 15, 20264 OWNERSHIP DOCUMENT EDGAR

The 335 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 33 such filings since October 2021, the latest 10:

  1. Jul 8, 2026SCHEDULE 13G/A
  2. Apr 22, 2026SCHEDULE 13D/A
  3. Mar 26, 2026SCHEDULE 13G/A
  4. Aug 14, 2025SCHEDULE 13G/A
  5. Jul 29, 2025SCHEDULE 13G/A
  6. Jul 3, 2025SCHEDULE 13D/A
  7. May 15, 2025SCHEDULE 13G
  8. Dec 26, 2024SCHEDULE 13D/A
  9. Nov 14, 2024SC 13G/A
  10. Nov 8, 2024SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Redmile Group, LLC12,872,946$34.8M2.3%No change
BlackRock, Inc.7,298,895$19.7M0.0%−2,769,719
Vanguard Portfolio Management LLC4,545,893$12.3M0.0%+411,308
Vanguard Capital Management LLC4,445,536$12.0M0.0%+253,473
Aqr Capital Management LLC3,837,229$10.4M0.0%+835,708
Two Sigma Investments, LP3,589,863$9.7M0.0%+123,077
Johnson & Johnson3,379,064$9.1M1.1%No change
Renaissance Technologies LLC2,983,268$8.1M0.0%+8,585
Millennium Management LLC2,433,978$6.6M0.0%New
Goldman Sachs Group Inc2,049,187$5.5M0.0%+721,430
Geode Capital Management, LLC1,322,013$3.6M0.0%−1,268,416
Jane Street Group, LLC1,027,007$2.8M0.0%+380,028
Citadel Advisors LLC993,308$2.7M0.0%+50,382
Bruce & Co., Inc.989,188$2.7M0.7%+200,000
Morgan Stanley694,580$1.9M0.0%−73,168
Vanguard Fiduciary Trust Co640,428$1.7M0.0%−13,333
Charles Schwab Investment Management Inc610,949$1.6M0.0%−145,324
UBS Group AG590,178$1.6M0.0%−1,231,537
Qube Research & Technologies Ltd578,150$1.6M0.0%New
Connor, Clark & Lunn Investment Management Ltd.574,995$1.6M0.0%+105,210
State Street Corp558,928$1.5M0.0%−1,704,245
DAFNA Capital Management LLC525,000$1.4M0.3%−25,000
Susquehanna International Group, Llp511,050$1.4M0.0%+212,554
Marshall Wace, Llp492,426$1.3M0.0%New
Ieq Capital, LLC487,728$1.3M0.0%+162,940

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jan 31, 2023Daniel S. GoldmanDemocratic, HouseSale$1,001 - $15,000+159.8%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47